ObesityPhase 2NCT07890376
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
A Phase 2 study testing LY4086940 in people with Obesity and Overweight, run by Eli Lilly and Company at 46 sites in 2 countries.
Trial summary
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Obesity, Overweight
- What is being tested?
- LY4086940
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 460 participants
- Where
- 46 sitesin 2 countries
- Study dates
- Nov 2026to Jun 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Meet inclusion criteria under Master Protocol CWMM (NCT06143956)
Who cannot join
- In addition to exclusion criteria under Master Protocol CWMM (NCT06143956)
- Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes
- Have a laboratory value suggestive of diabetes
- Have any of the following cardiovascular conditions within 6 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
Show all 10Show fewer
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a known personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma.
- Within 6 months prior to screening, have taken medications (prescribed or over the counter) or alternative remedies (including herbal or nutritional supplements) that promote weight loss
Trial locations and contacts
46 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
46 sites in 2 countries
United States39 sites
Dent Neurologic Institute
Amherst, New York, 14226
Laszlo Mechtler
Medical Research Partners
Ammon, Idaho, 83406
Joseph Moore
IMA Clinical Research Austin
Austin, Texas, 78745
Nomita Kim
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, 85225
Yessica Sachdeva
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640
Rupal Trivedi
CTI Clinical Research Center
Cincinnati, Ohio, 45212
James Maynard
StudyMetrix Research
City of Saint Peters, Missouri, 63303
Timothy Smith
Velocity Clinical Research, Dallas
Dallas, Texas, 75230
Dan Lender
FutureSearch Trials of Dallas
Dallas, Texas, 75251
Michael Downing
Sovah Clinical Research-River District
Danville, Virginia, 24541
Stephan Jannach
NorCal Medical Research, Inc
Greenbrae, California, 94904
Linda Gaudiani
Tribe Clinical Research, LLC
Greenville, South Carolina, 29607
Ronald Mayfield
Velocity Clinical Research, Huntington Park
Huntington Park, California, 90255
Stanley Hsia
Las Vegas Medical Research
Las Vegas, Nevada, 89128
Cornell Calinescu
New Horizon Research Center
Miami, Florida, 33165
Lazaro Nunez
Indago Research & Health Center, Inc
Miami Lakes, Florida, 33016
Jose Cardona
Monroe Biomedical Research
Monroe, North Carolina, 28112
Awawu Igbinadolor
Lucas Research, Inc
Morehead City, North Carolina, 28557
Kathryn Lucas
Quality Medical Research
Nashville, Tennessee, 37211
Saras Sharma
Knownwell
Needham, Massachusetts, 02492
Angela Fitch
Lucida Clinical Trials
New Bedford, Massachusetts, 02740
David Shih
Lucas Research, Inc.
New Bern, North Carolina, 28562
Joseph Maides
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652
Cathy Barnes
Charter Research - Winter Park
Orlando, Florida, 32803
Edgardo Rivera-Rivera
Rochester Clinical Research, LLC
Rochester, New York, 14609
Patrick Connors
Peninsula Research Associates
Rolling Hills Estates, California, 90274
LeighAnn Schmidt
Endeavor Clinical Trials
San Antonio, Texas, 78240
Nitendra Agarwal
Headlands Research - Scottsdale
Scottsdale, Arizona, 85260
Benjamin Clark
Headlands Research - Detroit
Southfield, Michigan, 48034
Christopher Romero
Clinvest Headlands Llc
Springfield, Missouri, 65807
Christina Capps
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905
David Radin
Charter Research - Lady Lake
The Villages, Florida, 32162
Jeffrey Norton
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606
susan brian
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098
Neil Fraser
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona, 85712
Anita Kohli
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598
Bonnie Kimmel
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, 98801
Kathryn Eren
Texas Valley Clinical Research
Weslaco, Texas, 78596
Eduardo Luna
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, 50266
Anuj Bhargava
Argentina7 sites
Cicemo Srl
Buenos Aires, 1424
Pablo Costanzo
CARDIAMET Investigaciones Médicas
Buenos Aires, C1014ACP
Angela Romero Zarante
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, C1056ABI
Federico Perez Manghi
Centro Médico Viamonte
Buenos Aires, C1120AAC
Diego Aizenberg
Mautalen Salud e Investigación
Buenos Aires, C1128AAF
Jose Fretes
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, C1425AGC
Evelyn Blanc
Instituto Médico Catamarca IMEC
Rosario, 2000
Natacha Maldonado
About this study
Official title: A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.
Participation in the study will last about 58 weeks.
- Conditions
- Obesity, Overweight
- Being tested
- LY4086940, Placebo
- Keywords
- Incretins, Weight loss, Overnutrition, GLP-1
- Medical subject headings
- Obesity, Overweight, Weight Loss, Overnutrition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LY4086940Drug
Administered orally
PlaceboDrug
Administered orally
| Study group | Role | What they receive |
|---|---|---|
| LY4086940 Dose 1 | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 2 | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 3, Titration Schedule A | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 3, Titration Schedule B | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 4 | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 5 | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 6, Titration Schedule A | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 6, Titration Schedule B | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| LY4086940 Dose 6, Titration Schedule C | Experimental | Participants will receive LY4086940 orally Receives: Drug: LY4086940 |
| Placebo | Placebo comparator | Participants will receive placebo orally Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 32
Secondary outcomes (4)
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 48
Change from Baseline Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)
Measured: Baseline, Week 32, Week 48
Pharmacokinetics (PK): Area Under the Curve (AUC) of LY4086940 for One Dosing Interval at Steady State
Measured: Week 48
PK: Maximum Concentration (Cmax) of LY4086940 at Steady State
Measured: Week 48
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionJan 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 460 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 M Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07890376
- Sponsor's protocol ID
- 27946
- Other IDs
- W8M-MC-OG01
- Status last verified
- Oct 2026
- First submitted
- 16 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.